Product
CT-P13
Aliases
CT-P13 SC (Infliximab)
4 clinical trials
4 indications
Indication
Crohn's diseaseIndication
ulcerative colitisIndication
Inflammatory Bowel DiseaseIndication
Rheumatologic DiseaseClinical trial
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderately to Severely Active Crohn's DiseaseStatus: Completed, Estimated PCD: 2022-08-23
Clinical trial
A Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative ColitisStatus: Completed, Estimated PCD: 2022-07-07
Clinical trial
The "PASSPORT Trial": Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active Crohn's Disease or Ulcerative Colitis.Status: Not yet recruiting, Estimated PCD: 2025-01-01
Clinical trial
EFFICACY AND SAFETY OF S.C. INFLIXIMAB IN PATIENTS SWITCHED FROM I.V. FORMULATION OF INFLIXIMABStatus: Recruiting, Estimated PCD: 2023-10-20